Fatty acid translocase: a culprit of lipid metabolism dysfunction in disease-Immunometabolism-CSCIED科技核心评价数据库-手机版

Fatty acid translocase: a culprit of lipid metabolism dysfunction in disease

Fatty acid translocase: a culprit of lipid metabolism dysfunction in disease

ES评分 0 浏览量：566 下载量：0

DOI	10.1097/IN9.0000000000000001
刊名	Immunometabolism IJ
年，卷(期)	2022, 4(3)
作者	Rupert, Joseph E.; Kolonin, Mikhail G.,
作者单位	[Rupert, Joseph E.; Kolonin, Mikhail G.] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA
摘要	Dysregulation of lipid deposition into and mobilization from white adipose tissue (WAT) underlies various diseases. Long-chain fatty acids (LCFA) and cholesterol trafficking in and out of adipocytes is a process relying on transporters shuttling lipids from the plasma membrane (PM) to lipid droplets (LD). CD36 is the fatty acid translocase (FAT) that transports LCFA and cholesterol across the PM. Interactions of CD36 with proteins PHB1, ANX2, and CAV1 mediate intercellular lipid transport between adipocytes, hematopoietic, epithelial, and endothelial cells. Intracellularly, the FAT complex has been found to regulate LCFA trafficking between the PM and LD. This process is regulated by CD36 glycosylation and S-acylation, as well as by post-translational modifications of PHB1 and ANX2, which determine both protein-protein interactions and the cellular localization of the complex. Changes in extracellular and intracellular LCFA levels have been found to induce the post-translational modifications and the function of the FAT complex in lipid uptake and mobilization. The role of the CD36/PHB1/ANX2 complex may span beyond lipid trafficking. The requirement of PHB1 for mitochondrial oxidative metabolism in brown adipocytes has been revealed. Cancer cells which take advantage of lipids mobilized by adipocytes and oxidized in leukocytes are indirectly affected by the function of FAT complex in other tissues. The direct importance of CD36 interaction with PHB1/and ANX2 in cancer cells remains to be established. This review highlights the multifaceted roles of the FAT complex in systemic lipid trafficking and discuss it as a potential target in metabolic disease and cancer.
Abstract	Dysregulation of lipid deposition into and mobilization from white adipose tissue (WAT) underlies various diseases. Long-chain fatty acids (LCFA) and cholesterol trafficking in and out of adipocytes is a process relying on transporters shuttling lipids from the plasma membrane (PM) to lipid droplets (LD). CD36 is the fatty acid translocase (FAT) that transports LCFA and cholesterol across the PM. Interactions of CD36 with proteins PHB1, ANX2, and CAV1 mediate intercellular lipid transport between adipocytes, hematopoietic, epithelial, and endothelial cells. Intracellularly, the FAT complex has been found to regulate LCFA trafficking between the PM and LD. This process is regulated by CD36 glycosylation and S-acylation, as well as by post-translational modifications of PHB1 and ANX2, which determine both protein-protein interactions and the cellular localization of the complex. Changes in extracellular and intracellular LCFA levels have been found to induce the post-translational modifications and the function of the FAT complex in lipid uptake and mobilization. The role of the CD36/PHB1/ANX2 complex may span beyond lipid trafficking. The requirement of PHB1 for mitochondrial oxidative metabolism in brown adipocytes has been revealed. Cancer cells which take advantage of lipids mobilized by adipocytes and oxidized in leukocytes are indirectly affected by the function of FAT complex in other tissues. The direct importance of CD36 interaction with PHB1/and ANX2 in cancer cells remains to be established. This review highlights the multifaceted roles of the FAT complex in systemic lipid trafficking and discuss it as a potential target in metabolic disease and cancer.
关键词	fatty acid translocase; lipid metabolism
KeyWord	fatty acid translocase; lipid metabolism
基金项目
页码	1-5

参考文献
相关文献

[1]. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell. 2014;156(1–2):20–44. doi: 10.1016/j.cell.2013.12.012.

[2]. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc. 2012;71(2):332–8. doi: 10.1017/S0029665112000092.

[3]. Yazici D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol. 2017;960:277–304.

[4]. Kajimura S, Spiegelman BM, Seale P. Brown and beige fat: physiological roles beyond heat generation. Cell Metab. 2015;22(4):546–59. doi: 10.1016/j.cmet.2015.09.007.

[5]. Morigny P, Boucher J, Arner P, et al. Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics. Nat Rev Endocrinol. 2021;17(5):276–95. doi: 10.1038/s41574-021-00471-8.

[6]. Goossens GH. The metabolic phenotype in obesity: fat mass, body fat distribution, and adipose tissue function. Obes Facts. 2017;10(3):207–15. doi: 10.1159/000471488.

[7]. Lytrivi M, Castell AL, Poitout V, et al. Recent insights into mechanisms of beta-cell lipo- and glucolipotoxicity in type 2 diabetes. J Mol Biol. 2020;432(5):1514–34. doi: 10.1016/j.jmb.2019.09.016.

[8]. Rupert JE, Narasimhan A, Jengelley DHA, et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J Exp Med. 2021;218(6):e20190450.

[9]. Quail DF, Dannenberg AJ. The obese adipose tissue microenvironment in cancer development and progression. Nat Rev Endocrinol. 2019;15(3):139–54. doi: 10.1038/s41574-018-0126-x.

[10]. Bacci M, Lorito N, Smiriglia A, et al. Fat and furious: lipid metabolism in antitumoral therapy response and resistance. Trends Cancer. 2021;7(3):198–213. doi: 10.1016/j.trecan.2020.10.004.

[11]. Pepino MY, Kuda O, Samovski D, et al. Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr. 2014;34:281–303. doi: 10.1146/annurev-nutr-071812-161220.

[12]. Glatz JF, Luiken JJ, Bonen A. Membrane fatty acid transporters as regulators of lipid metabolism: implications for metabolic disease. Physiol Rev. 2010;90(1):367–417. doi: 10.1152/physrev.00003.2009.

[13]. Canton J, Neculai D, Grinstein S. Scavenger receptors in homeostasis and immunity. Nat Rev Immunol. 2013;13(9):621–34. doi: 10.1038/nri3515.

[14]. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009;2(72):re3.

[15]. Asch AS, Silbiger S, Heimer E, et al. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem Biophys Res Commun. 1992;182(3):1208–17. doi: 10.1016/0006-291x(92)91860-s.

[16]. Yang P, Su C, Luo X, et al. Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway. Cancer Lett. 2018;438:76–85. doi: 10.1016/j.canlet.2018.09.006.

[17]. Luo X, Zheng E, Wei L, et al. The fatty acid receptor CD36 promotes HCC progression through activating Src/PI3K/AKT axis-dependent aerobic glycolysis. Cell Death Dis. 2021;12(4):328. doi: 10.1038/s41419-021-03596-w.

[18]. Gilbertson TA, Khan NA. Cell signaling mechanisms of oro-gustatory detection of dietary fat: advances and challenges. Prog Lipid Res. 2014;53:82–92. doi: 10.1016/j.plipres.2013.11.001.

[19]. Zhou D, Samovski D, Okunade AL, et al. CD36 level and trafficking are determinants of lipolysis in adipocytes. FASEB J. 2012;26(11):4733–42. doi: 10.1096/fj.12-206862.

[20]. Su T, Huang C, Yang C, et al. Apigenin inhibits STAT3/CD36 signaling axis and reduces visceral obesity. Pharmacol Res. 2020;152:104586. doi: 10.1016/j.phrs.2019.104586.

[21]. Yang J, Park KW, Cho S. Inhibition of the CD36 receptor reduces visceral fat accumulation and improves insulin resistance in obese mice carrying the BDNF-Val66Met variant. J Biol Chem. 2018;293(34):13338–48.

[22]. Yang M, Silverstein RL. CD36 signaling in vascular redox stress. Free Radic Biol Med. 2019;136:159–71. doi: 10.1016/j.freeradbiomed.2019.02.021.

[23]. Cifarelli V, Appak-Baskoy S, Peche VS, et al. Visceral obesity and insulin resistance associate with CD36 deletion in lymphatic endothelial cells. Nat Commun. 2021;12(1):3350. doi: 10.1038/s41467-021-23808-3.

[24]. Febbraio M, Hajjar DP, Silverstein RL. CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108(6):785–91.

[25]. Ackers I, Szymanski C, Duckett KJ, et al. Blocking Wnt5a signaling decreases CD36 expression and foam cell formation in atherosclerosis. Cardiovasc Pathol. 2018;34:1–8. doi: 10.1016/j.carpath.2018.01.008.

[26]. Jia Q, Cao H, Shen D, et al. Quercetin protects against atherosclerosis by regulating the expression of PCSK9, CD36, PPARγ, LXRα and ABCA1. Int J Mol Med. 2019;44(3):893–902. doi: 10.3892/ijmm.2019.4263.

[27]. Fan Y, Yang J, Li H, et al. SNX10 deficiency restricts foam cell formation and protects against atherosclerosis by suppressing CD36-Lyn axis. Can J Cardiol. 2020. doi: 10.1016/j.cjca.2020.05.010.

[28]. Xia X, Hu T, He J, et al. USP10 deletion inhibits macrophage-derived foam cell formation and cellular-oxidized low density lipoprotein uptake by promoting the degradation of CD36. Aging. 2020;12(22):22892–905. doi: 10.18632/aging.104003.

[29]. Lin HY, Wang FS, Yang YL, et al. MicroRNA-29a Suppresses CD36 to ameliorate high fat diet-induced steatohepatitis and liver fibrosis in mice. Cells. 2019;8(10):12981298. doi: 10.3390/cells8101298.

[30]. Zhang C, Luo X, Chen J, et al. Osteoprotegerin promotes liver steatosis by targeting the ERK-PPAR-γ-CD36 pathway. Diabetes. 2019;68(10):1902–14. doi: 10.2337/db18-1055.

[31]. Glatz JFC, Luiken JJFP. Dynamic role of the transmembrane glycoprotein CD36 (SR-B2) in cellular fatty acid uptake and utilization. J Lipid Res. 2018;59(7):1084–93.

[32]. Cifarelli V, Ivanov S, Xie Y, et al. CD36 deficiency impairs the small intestinal barrier and induces subclinical inflammation in mice. Cell Mol Gastroenterol Hepatol. 2017;3(1):82–98. doi: 10.1016/j.jcmgh.2016.09.001.

[33]. Zhao L, Varghese Z, Moorhead JF, et al. CD36 and lipid metabolism in the evolution of atherosclerosis. Br Med Bull. 2018;126(1):101–12. doi: 10.1093/bmb/ldy006.

[34]. Verpoorten S, Sfyri P, Scully D, et al. Loss of CD36 protects against diet-induced obesity but results in impaired muscle stem cell function, delayed muscle regeneration and hepatic steatosis. Acta Physiol. 2020;228(3):e13395.

[35]. Grajchen E, Wouters E, van de Haterd B, et al. CD36-mediated uptake of myelin debris by macrophages and microglia reduces neuroinflammation. J Neuroinflammation. 2020;17(1):224. doi: 10.1186/s12974-020-01899-x.

[36]. Hoosdally SJ, Andress EJ, Wooding C, et al. The Human Scavenger Receptor CD36: glycosylation status and its role in trafficking and function. J Biol Chem. 2009;284(24):16277–88. doi: 10.1074/jbc.M109.007849.

[37]. Abumrad NA, el-Maghrabi MR, Amri EZ, et al. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem. 1993;268(24):17665–8.

[38]. Wang J, Hao JW, Wang X, et al. DHHC4 and DHHC5 facilitate fatty acid uptake by palmitoylating and targeting CD36 to the plasma membrane. Cell Rep. 2019;26(1):209–21.e5. doi: 10.1016/j.celrep.2018.12.022.

[39]. Salameh A, Daquinag AC, Staquicini DI, et al. Prohibitin/annexin 2 interaction regulates fatty acid transport in adipose tissue. JCI Insight. 2016;1(10):e86351.

[40]. Daquinag AC, Gao Z, Fussell C, et al. Fatty acid mobilization from adipose tissue is mediated by CD36 posttranslational modifications and intracellular trafficking. JCI Insight. 2021;6(17):e147057.

[41]. Kathiria AS, Butcher LD, Feagins LA, et al. Prohibitin 1 modulates mitochondrial stress-related autophagy in human colonic epithelial cells. PLoS One. 2012;7(2):e31231. doi: 10.1371/journal.pone.0031231.

[42]. Theiss AL, Idell RD, Srinivasan S, et al. Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J. 2007;21(1):197–206. doi: 10.1096/fj.06-6801com.

[43]. Mielenz D, Vettermann C, Hampel M, et al. Lipid rafts associate with intracellular B cell receptors and exhibit a B cell stage-specific protein composition. J Immunol. 2005;174(6):3508–17. doi: 10.4049/jimmunol.174.6.3508.

[44]. Wang S, Fusaro G, Padmanabhan J, et al. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene. 2002;21(55):8388–96. doi: 10.1038/sj.onc.1205944.

[45]. Kube E, Becker T, Weber K, et al. Protein-protein interaction studied by site-directed mutagenesis. Characterization of the annexin II-binding site on p11, a member of the S100 protein family. J Biol Chem. 1992;267(20):14175–82.

[46]. Johnsson N, Weber K. Alkylation of cysteine 82 of p11 abolishes the complex formation with the tyrosine-protein kinase substrate p36 (annexin 2, calpactin 1, lipocortin 2). J Biol Chem. 1990;265(24):14464–8.

[47]. Waisman DM. Annexin II tetramer: structure and function. Mol Cell Biochem. 1995;149–50:301–22.

[48]. Yurugi H, Tanida S, Ishida A, et al. Expression of prohibitins on the surface of activated T cells. Biochem Biophys Res Commun. 2012;420(2):275–80. doi: 10.1016/j.bbrc.2012.02.149.

[49]. Jackson DN, Panopoulos M, Neumann WL, et al. Mitochondrial dysfunction during loss of prohibitin 1 triggers Paneth cell defects and ileitis. Gut. 2020;69(11):1928–38. doi: 10.1136/gutjnl-2019-319523.

[50]. Nijtmans LG, de Jong L, Artal Sanz M, et al. Prohibitins act as a membrane-bound chaperone for the stabilization of mitochondrial proteins. EMBO J. 2000;19(11):2444–51. doi: 10.1093/emboj/19.11.2444.

[51]. Xu Y, Shen J, Ran Z. Emerging views of mitophagy in immunity and autoimmune diseases. Autophagy. 2020;16(1):3–17. doi: 10.1080/15548627.2019.1603547.

[52]. Liu D, Lin Y, Kang T, et al. Mitochondrial dysfunction and adipogenic reduction by prohibitin silencing in 3T3-L1 cells. PLoS One. 2012;7(3):e34315. doi: 10.1371/journal.pone.0034315.

[53]. Gao Z, Daquinag AC, Fussell C, et al. Prohibitin inactivation in adipocytes results in reduced lipid metabolism and adaptive thermogenesis impairment. Diabetes. 2021;70(10):2204–12. doi: 10.2337/db21-0094.

[54]. Jiang L, Dong P, Zhang Z, et al. Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells. Cell Death Dis. 2015;6:e1660. doi: 10.1038/cddis.2015.40.

[55]. Zhang J, Yin Y, Wang J, et al. Prohibitin regulates mTOR pathway via interaction with FKBP8. Front Med. 2021;15(3):448–59. doi: 10.1007/s11684-020-0805-6.

[56]. Jin X, Xie J, Zabolocki M, et al. The prohibitin-binding compound fluorizoline affects multiple components of the translational machinery and inhibits protein synthesis. J Biol Chem. 2020;295(29):9855–67. doi: 10.1074/jbc.RA120.012979.

[57]. Ising C, Brinkkoetter PT. Prohibitin signaling at the kidney filtration barrier. Adv Exp Med Biol. 2017;982:563–75. doi: 10.1007/978-3-319-55330-6_29.

[58]. Bharadwaj A, Bydoun M, Holloway R, et al. Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013;14(3):6259–305. doi: 10.3390/ijms14036259.

[59]. Gabel M, Chasserot-Golaz S. Annexin A2, an essential partner of the exocytotic process in chromaffin cells. J Neurochem. 2016;137(6):890–6. doi: 10.1111/jnc.13628.

[60]. Gabel M, Delavoie F, Demais V, et al. Annexin A2-dependent actin bundling promotes secretory granule docking to the plasma membrane and exocytosis. J Cell Biol. 2015;210(5):785–800. doi: 10.1083/jcb.201412030.

[61]. Maan M, Peters JM, Dutta M, et al. Lipid metabolism and lipophagy in cancer. Biochem Biophys Res Commun 2018;504(3):582–9. doi: 10.1016/j.bbrc.2018.02.097.

[62]. Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 2020;31(1):62–76. doi: 10.1016/j.cmet.2019.11.010.

[63]. Lengyel E, Makowski L, DiGiovanni J, et al. Cancer as a matter of fat: the crosstalk between adipose tissue and tumors. Trends Cancer. 2018;4(5):374–84. doi: 10.1016/j.trecan.2018.03.004.

[64]. Zhong X, Yang Y, Li B, et al. Downregulation of SLC27A6 by DNA hypermethylation promotes proliferation but suppresses metastasis of nasopharyngeal carcinoma through modulating lipid metabolism. Front Oncol. 2021;11:780410. doi: 10.3389/fonc.2021.780410.

[65]. Wang R, Tao B, Fan Q, et al. Fatty-acid receptor CD36 functions as a hydrogen sulfide-targeted receptor with its Cys333-Cys272 disulfide bond serving as a specific molecular switch to accelerate gastric cancer metastasis. EBioMedicine. 2019;45:108–23. doi: 10.1016/j.ebiom.2019.06.037.

[66]. Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Theranostics. 2019;9(17):4893–908. doi: 10.7150/thno.36037.

[67]. Chen YJ, Liao WX, Huang SZ, et al. Prognostic and immunological role of CD36: a pan-cancer analysis. J Cancer. 2021;12(16e):4762–73. 10.7150/jca.50502.

[68]. Feng WW, Wilkins O, Bang S, et al. CD36-Mediated metabolic rewiring of breast cancer cells promotes resistance to HER2-Targeted therapies. Cell Rep. 2019;29(11):3405–20.e5. doi: 10.1016/j.celrep.2019.11.008.

[69]. DeFilippis RA, Chang H, Dumont N, et al. CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012;2(9):826–39. doi: 10.1158/2159-8290.CD-12-0107.

[70]. Nath A, Chan C. Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Sci Rep. 2016;6:18669. doi: 10.1038/srep18669.

[71]. Pascual G, Avgustinova A, Mejetta S, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541(7635):41–5. doi: 10.1038/nature20791.

[72]. Deng M, Cai X, Long L, et al. CD36 promotes the epithelial-mesenchymal transition and metastasis in cervical cancer by interacting with TGF-β. J Transl Med. 2019;17(1):352. doi: 10.1186/s12967-019-2098-6.

[73]. Ladanyi A, Mukherjee A, Kenny HA, et al. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018;37(17):2285–301. doi: 10.1038/s41388-017-0093-z.

[74]. Corbet C, Bastien E, Santiago de Jesus JP, et al. TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 2020;11(1):454. doi: 10.1038/s41467-019-14262-3.

[75]. Gyamfi J, Yeo JH, Kwon D, et al. Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer. NPJ Breast Cancer. 2021;7(1):129. doi: 10.1038/s41523-021-00324-7.

[76]. Nath A, Li I, Roberts LR, et al. Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma. Sci Rep. 2015;5:14752. doi: 10.1038/srep14752.

[77]. Nan P, Dong X, Bai X, et al. Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin α. Cancer Lett. 2022;528:59–75. doi: 10.1016/j.canlet.2021.12.025.

[78]. Wang H, Franco F, Tsui YC, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat Immunol. 2020;21(3):298–308. doi: 10.1038/s41590-019-0589-5.

[79]. Xu S, Chaudhary O, Rodríguez-Morales P, et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8. Immunity. 2021;54(7):1561–77.e7. doi: 10.1016/j.immuni.2021.05.003.

[80]. Su P, Wang Q, Bi E, et al. Enhanced lipid accumulation and metabolism are required for the differentiation and activation of tumor-associated macrophages. Cancer Res. 2020;80(7):1438–50. doi: 10.1158/0008-5472.CAN-19-2994.

[81]. Jabbari K, Winkelmaier G, Andersen C, et al. Protein ligands in the secretome of CD36+ Fibroblasts Induce Growth Suppression in a Subset of Breast Cancer Cell Lines.. Cancers. 2021;13(18):45214521. doi: 10.3390/cancers13184521.

[82]. Ho MY, Liang CM, Liang SM. MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis. Oncotarget. 2015;6(1):381–93. doi: 10.18632/oncotarget.2804.

[83]. Cho SY, Kang S, Kim DS, et al. HSP27, ALDH6A1 and Prohibitin act as a trio-biomarker to predict survival in late metastatic prostate cancer. Anticancer Res. 2018;38(11):6551–60. doi: 10.21873/anticanres.13021.

[84]. Huang X, Liu J, Ma Q. Prohibitin participates in the HIRA complex to promote cell metastasis in breast cancer cell lines. FEBS Open Bio. 2020;10(10):2182–90. doi: 10.1002/2211-5463.12966.

[85]. Maji S, Chaudhary P, Akopova I, et al. Exosomal annexin II promotes angiogenesis and breast cancer metastasis. Mol Cancer Res. 2017;15(1):93–105. doi: 10.1158/1541-7786.MCR-16-0163.

[86]. Zhang M, Di Martino JS, Bowman RL, et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins. Cancer Discov. 2018;8(8):1006–25. doi: 10.1158/2159-8290.CD-17-1371.

[87]. Jeanne A, Schneider C, Martiny L, et al. Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front Pharmacol. 2015;6:252. doi: 10.3389/fphar.2015.00252.

[88]. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol. 2008;1:20. doi: 10.1186/1756-8722-1-20.

[89]. Kolonin MG, Saha PK, Chan L, et al. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10(6):625–32. doi: 10.1038/nm1048.

[90]. Daquinag AC, Zhang Y, Amaya-Manzanares F, et al. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell. 2011;9(1):74–86.

[91]. Daquinag AC, Tseng C, Zhang Y, et al. Targeted proapoptotic peptides depleting adipose stromal cells inhibit tumor growth. Mol Ther. 2016;24(1):34–40. doi: 10.1038/mt.2015.155.

[92]. Daquinag AC, Tseng C, Salameh A, et al. Depletion of white adipocyte progenitors induces beige adipocyte differentiation and suppresses obesity development. Cell Death Differ. 2015;22(2):351–63. doi: 10.1038/cdd.2014.148.

[93]. Subramanian S, Daquinag AC, AghaAmiri S, et al. Characterization of peptides targeting metastatic tumor cells as probes for cancer detection and vehicles for therapy delivery. Cancer Res. 2021;81(22):5756–64.

[94]. Wu CH, Liu IJ, Lu RM, et al. Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci. 2016;23:8.

[95]. Gao Z, Daquinag AC, Yu Y, et al. Endothelial prohibitin mediates bidirectional long-chain fatty acid transport in white and brown adipose tissues. Diabetes. 2022;2. doi: 10.2337/db21-0972.

引用本文

Rupert, Joseph E.; Kolonin, Mikhail G.. Fatty acid translocase: a culprit of lipid metabolism dysfunction in disease [J]. Immunometabolism. 2022; 4; (3). 1 - 5.

文献评论

相关学者

相关机构